Effect of Aerobic and Resistance Exercise on Cardiac Adipose Tissue; Secondary Analyses From a Randomized Clinical Trial

JAMA Cardiol. 2019 Jul 3. doi: 10.1001/jamacardio.2019.2074.

Abstract

IMPORTANCE:
Epicardial and pericardial adipose tissues are emerging as important risk factors for cardiovascular disease, and there is a growing interest in discovering strategies to reduce the accumulation of fat in these depots.
OBJECTIVE:
To investigate whether a 12-week endurance or resistance training intervention regulates epicardial and pericardial adipose tissue mass.
DESIGN, SETTING, AND PARTICIPANTS:
Secondary analysis of a randomized, assessor-blinded clinical trial initiated on August 2016 and completed April 2018. This single-center, community-based study included 50 physically inactive participants with abdominal obesity.
INTERVENTIONS:
Participants were randomized to a supervised high-intensity interval endurance training (3 times a week for 45 minutes), resistance training (3 times a week for 45 minutes), or no exercise (control group).
MAIN OUTCOMES AND MEASURES:
Change in epicardial and pericardial adipose tissue mass assessed by magnetic resonance imaging, based on a prespecified secondary analysis plan including 3 of 5 parallel groups.
RESULTS:
Of 50 participants (mean [SD] age, 41 [14] years, 10 men [26%]; mean [SD] body mass index [calculated as weight in kilograms divided by height in meters squared], 32 [5]), 39 [78%] completed the study. Endurance training and resistance training reduced epicardial adipose tissue mass by 32% (95% CI, 10%-53%) and 24% (95% CI, 1%-46%), respectively, compared with the no exercise control group (56% [95% CI, 24%-88%]; P = .001 and 48% [95% CI, 15%-81%]; P < .001, respectively). While there was a nonsignificant reduction in pericardial adipose tissue mass after endurance training (11% [95% CI, -5% to 27%]; P = .17), resistance training significantly reduced pericardial adipose tissue mass by 31% (95% CI, 16%-47%; P < .001) when compared with the no exercise control group. Compared with the no exercise control group, there was an increase in left ventricular mass by endurance (20 g [95% CI, 11%-30%]; P < .001) and resistance training (18 g [95% CI, 8%-28%]; P < .001). Other cardiometabolic outcomes remained unchanged after the 12-week trial period.
CONCLUSION AND RELEVANCE:
In individuals with abdominal obesity, both endurance and resistance training reduced epicardial adipose tissue mass, while only resistance training reduced pericardial adipose tissue mass. These data highlight the potential preventive importance of different exercise modalities as means to reduce cardiac fat in individuals with abdominal obesity.

OBESITY and SARCOPENIA

OBESITY and SARCOPENIA

BODY COMPOSITION

When conducting an obesity trial to measure body composition, it’s important to choose imaging options that provide accurate and reliable results. Here are some of the best imaging modalities commonly used for this purpose:

  • Dual-Energy X-ray Absorptiometry (DXA): DXA scans are highly accurate and are considered the gold standard for measuring body composition. They can provide information about bone density, fat mass, and lean mass.
  • Computed Tomography (CT) Scan: CT scans can offer detailed information about fat distribution within the body, allowing for precise measurements of visceral and subcutaneous fat.
  • Magnetic Resonance Imaging (MRI): MRI can provide excellent visualization of fat and lean tissue, offering insights into body composition. It’s non-invasive and does not involve radiation.
  • Bioelectrical Impedance Analysis (BIA): While not an imaging modality in the traditional sense, BIA uses electrical impedance to estimate body composition. It’s relatively simple and cost-effective.
  • Ultrasound: Ultrasound imaging can be used to assess the subcutaneous fat thickness and muscle thickness at specific locations, making it useful for localized body composition measurements.
  • Air Displacement Plethysmography (ADP): ADP, commonly measured using the BodPod, calculates body composition based on the principles of air displacement. It’s non-invasive and provides accurate results.
  • Positron Emission Tomography (PET) Scan: PET scans can be used to assess metabolic activity in fat tissue, providing insights into obesity-related metabolic changes.

The choice of imaging modality should depend on factors such as the specific research goals, budget, and accessibility of equipment. It’s often advisable to consult with a medical imaging expert or radiologist to determine the most suitable option for your obesity trial. Additionally, consider ethical and safety aspects when conducting imaging studies involving human participants

About IAG, Image Analysis Group

IAG is a unique partner to life sciences companies developing new treatment and driving the hope of the up-coming precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™, our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes.

Acting as imaging Contract Research Organization, IAG’s experts also recognize the significance of a comprehensive approach to asset development. They actively engage in co-development projects with both private and public sectors, demonstrating a commitment to cultivating collaboration and advancing healthcare solutions.

Contact our expert team: imaging.experts@ia-grp.com

READ NEXT CASE STUDY >
Experience: Scoring Systems
  • Eligibility and Safety Assessments
  • Body Mass Index (BMI) Score
  • Visceral Adiposity Index (VAI)
  • Fat Mass Index (FMI)
  • Fat-Free Mass Index (FFMI)
  • Total Body Fat Percentage
  • Sarcopenia Index
  • Epicardial Fat Volume Score
  • Liver Fat Score
  • Muscle Quality Score
  • Phase Angle (PhA)
Experience: Imaging
  • MRI
  • DEXA
  • CT
  • PET, PET-CT
  • Ultrasound
  • ADP
  • BIA
Publications

Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.

Testimonials

Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.